Please visit answersincme.com/PHE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast oncology discusses the significant of HER2 in the targeted treatment of advanced breast cancer. Upon completion of this activity, participants should be better able to: Identify optimal strategies to assess HER2-low expression in both primary and recurrent tumors in patients with breast cancer; Describe the clinical significance of the latest safety and efficacy data for HER2-targeted antibody drug conjugates in the treatment of patients with HER2-low advanced breast cancer; and Predict the role that HER2-targeted antibody drug conjugates might play in the treatment of pretreated patients with HER2-low advanced breast cancer.

Please visit answersincme.com/NSY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses neoadjuvant systemic treatment of resectable non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Outline opportunities for improvement over the currently recommended neoadjuvant systemic regimens for patients with resectable NSCLC; Explain the clinical implications of emerging data evaluating chemo-immunotherapeutic approaches for the neoadjuvant treatment of resectable NSCLC; and Describe how to develop a personalized, evidence-based treatment plan for patients with resectable NSCLC.

Please visit answersincme.com/NMC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses rationale for—and clinical impact of—cereblon (CRBN) E3 ligase modulators (CELMoDs) in treating relapsed/refractory multiple myeloma (RRMM), including clinical considerations for their future use. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for investigating novel therapies to address unmet treatment needs for relapsed/refractory multiple myeloma; Review the biologic rationale for targeting cereblon with novel therapies for RRMM; Describe the clinical impact of emerging CRBN E3 ligase modulators in patients with RRMM; and Outline clinical considerations for the integration of CRBN E3 ligase modulators in the future management of RRMM.

Please visit answersincme.com/EUT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses glioblastoma multiforme (GBM). Upon completion of this activity, participants should be better able to: Identify opportunities to personalize adjuvant treatment for patients with newly diagnosed glioblastoma multiforme (GBM); Describe practical approaches to manage adverse events associated with adjuvant therapies in patients with newly diagnosed GBM; and Outline strategies to monitor patients with newly diagnosed GBM on adjuvant therapies to improve patient outcomes.

Please visit answersincme.com/VSA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses how racial disparities may impact the management of Black patients with anemia of chronic kidney disease (CKD) and how to address these disparities. Upon completion of this activity, participants should be better able to: Identify the racial disparities that affect Black patients with anemia of CKD, leading to suboptimal outcomes; Recognize underlying factors contributing to racial disparities in the management of Black patients with anemia of CKD; and Outline strategies to improve the individualized treatment and management of anemia of CKD among Black patients.

Please visit answersincme.com/KAG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert on immunization discusses the mechanisms of COVID-19 vaccines, the clinical impact of viral vector–based vaccines and how to improve communication with patients regarding vaccine uptake. Upon completion of this activity, participants should be better able to: Recognize the mechanism of action of available COVID-19 vaccines; Evaluate the clinical impact of available viral vector–based COVID-19 vaccines; and Apply patient-centered counseling strategies to enhance communication with patients to improve COVID-19 vaccine acceptance.

Please visit answersincme.com/BZG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses new evidence for targeting PD-1/PD-L1 inhibition in locally advanced cervical cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for therapeutically targeting the PD-1/PD-L1 axis to address unmet treatment needs in locally advanced cervical cancer; Describe ongoing studies and preliminary evidence for late-stage emerging PD-1/PD-L1 inhibitors being investigated for the treatment of locally advanced cervical cancer; and Outline current and potential future roles of PD-1/PD-L1 inhibitors in cervical cancer management.

Please visit answersincme.com/AXF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic cancers discusses the potential role of combination poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors (ICIs) in improving outcomes in advanced ovarian cancer.Upon completion of this activity, participants should be better able to: Discuss the clinical rationale for combining PARP inhibitors with ICIs; Review the clinical profile of PARP inhibitors in combination with ICIs for patients with advanced ovarian cancer; and Identify the potential place in therapy for PARP inhibitors in combination with ICIs in advanced ovarian cancer.

Please visit answersincme.com/BTD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses available and emerging frontline dual immunotherapy plus chemotherapy combination regimens for the treatment of patients with advanced non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be able to: Review the role of PD-L1 expression in the selection of frontline immunotherapeutic regimens for patients with advanced NSCLC, with a focus on available and emerging frontline dual immunotherapy and chemotherapy combination regimens; Describe the clinical profiles of available and emerging frontline dual immunotherapy plus chemotherapy combination regimens for the treatment of patients with advanced NSCLC; and Outline strategies to integrate available and emerging dual immunotherapy and chemotherapy combination regimens into frontline settings through optimal patient selection and management.

Please visit answersincme.com/MDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the impact of adjuvant immune checkpoint inhibitors (ICIs) on outcomes in patients with resected early-stage non-small cell lung cancer (NSCLC), and how to optimally integrate them into practice based on recent evidence. Upon completion of this activity, participants should be better able to: Review guideline-recommended adjuvant treatment options for patients with surgically resected early-stage NSCLC; Describe the clinical evidence for novel ICIs being investigated for the adjuvant treatment of surgically resected early-stage NSCLC; and Outline clinical considerations for the use of novel adjuvant ICIs in the management of patients with surgically resected early-stage NSCLC.